Is ERIS Lifescience technically bullish or bearish?
2025-12-02 09:41:23Recent Technical Trend Shift After a period of mild bullishness, ERIS Lifescience’s technical trend has transitioned to a sideways movement. This change suggests a phase of consolidation where neither buyers nor sellers dominate decisively. Such a pattern often indicates market indecision, with the stock price oscillating within a range rather than trending strongly upwards or downwards. The current price stands at ₹1,582.80, slightly below the previous close of ₹1,595.30. The stock’s 52-week high is ₹1,909.55, while the low is ₹1,130.05, indicating a significant range of price movement over the past year. Today’s trading range has been relatively narrow, with a high of ₹1,595.90 and a low of ₹1,575.00, reinforcing the sideways momentum. Key Technical In...
Read More
ERIS Lifesciences Technical Momentum Shifts Amid Mixed Market Signals
2025-12-02 08:11:00ERIS Lifesciences has experienced a notable shift in its technical momentum, moving from a mildly bullish trend to a sideways pattern. This change is underscored by a complex interplay of technical indicators, including MACD, RSI, and moving averages, reflecting a nuanced market assessment for the pharmaceutical and biotechnology company.
Read More
ERIS Lifescience Sees Revision in Market Evaluation Amid Mixed Financial Signals
2025-11-27 10:06:45ERIS Lifescience has undergone a revision in its market evaluation, reflecting a nuanced shift in its financial and technical outlook. The pharmaceutical and biotechnology company’s recent assessment highlights a blend of strong operational metrics alongside valuation concerns, prompting a reassessment of its investment appeal.
Read MoreWhy is ERIS Lifescience falling/rising?
2025-11-19 23:24:03As of 19-Nov, ERIS Lifesciences Ltd is experiencing a price increase, currently at Rs 1,608.00, reflecting a rise of Rs 34.0 or 2.16%. The stock has shown strong performance today, outperforming its sector by 2.09% and achieving a consecutive gain over the last four days, with a total return of 6.04% during this period. Additionally, the stock has demonstrated impressive returns over various time frames, including a 17.47% increase year-to-date and a substantial 137.62% rise over the past three years. The company's high management efficiency, as indicated by a return on capital employed (ROCE) of 16.70%, and a low debt to EBITDA ratio of 1.32 times, further support its positive outlook. Moreover, the company has reported positive results for the last three consecutive quarters, contributing to investor confidence. In the broader market context, the stock's short-term return of 2.17% over the past week sign...
Read MoreIs ERIS Lifescience technically bullish or bearish?
2025-11-17 08:08:54As of 14 November 2025, the technical trend for ERIS Lifescience has changed from sideways to mildly bullish. The current stance is mildly bullish, driven primarily by the daily moving averages indicating bullish momentum. However, the weekly MACD and KST remain mildly bearish, suggesting some caution in the short term. The monthly MACD is bullish, providing a stronger long-term outlook. The Bollinger Bands show a mixed signal with a bearish weekly stance and a mildly bullish monthly view. Overall, while there are bullish indicators, the presence of bearish signals in the weekly timeframe indicates a cautious approach is warranted....
Read More
Eris Lifesciences Shows Mixed Technical Trends Amid Strong Long-Term Performance
2025-11-17 08:03:52Eris Lifesciences, a small-cap pharmaceutical company, has recently revised its evaluation amid changing market conditions. The stock has shown strong performance over the past year, significantly outperforming the Sensex. Technical indicators present a mixed outlook, reflecting varying trends on weekly and monthly bases. Long-term returns remain impressive.
Read MoreIs ERIS Lifescience technically bullish or bearish?
2025-11-16 08:09:33As of 14 November 2025, the technical trend for ERIS Lifescience has changed from sideways to mildly bullish. The current stance is mildly bullish, supported by the daily moving averages indicating a positive trend. However, the weekly MACD and KST are both mildly bearish, suggesting some caution. The monthly MACD remains bullish, providing a stronger long-term outlook. The Bollinger Bands show a mixed signal with a bearish stance on the weekly and a mildly bullish on the monthly. Overall, while there are some bearish indicators in the weekly data, the shift to mildly bullish and the strength in daily moving averages indicate a generally positive short-term outlook....
Read MoreIs ERIS Lifescience technically bullish or bearish?
2025-11-15 08:16:12As of 14 November 2025, the technical trend for ERIS Lifescience has changed from sideways to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating a positive trend. However, the weekly MACD and KST are mildly bearish, which suggests some caution. The monthly MACD is bullish, providing a stronger long-term outlook. The Bollinger Bands show a mixed signal with a bearish stance on the weekly and a mildly bullish stance on the monthly. Overall, while there are some bearish indicators in the shorter time frames, the shift to a mildly bullish trend indicates a potential for upward movement in the near term....
Read MoreHow has been the historical performance of ERIS Lifescience?
2025-11-15 00:09:08Answer: The historical performance of ERIS Lifescience shows significant growth in net sales and operating profit over the years, with net sales reaching 2,893.64 Cr in March 2025, up from 1,074.06 Cr in March 2020. The operating profit (PBDIT) also increased to 1,035.56 Cr in March 2025 from 376.60 Cr in March 2019. However, profit after tax saw fluctuations, peaking at 406.11 Cr in March 2022 before declining to 351.84 Cr in March 2025. The company's total assets grew from 1,381.39 Cr in March 2020 to 6,744.13 Cr in March 2025, while total liabilities increased from 1,381.39 Cr to 6,744.13 Cr in the same period. Cash flow from operating activities improved significantly, reaching 1,065.00 Cr in March 2025 compared to 271.00 Cr in March 2020. Breakdown: ERIS Lifescience has demonstrated a robust upward trend in its financial performance, particularly in net sales, which surged from 1,074.06 Cr in March 20...
Read MoreAnnouncement under Regulation 30 (LODR)-Allotment
16-Jan-2026 | Source : BSEAllotment of 2306372 equity shares of the Company
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
12-Jan-2026 | Source : BSEAs Attached
Closure of Trading Window
29-Dec-2025 | Source : BSEas attached
Corporate Actions
No Upcoming Board Meetings
ERIS Lifesciences Ltd has declared 735% dividend, ex-date: 13 Feb 25
No Splits history available
No Bonus history available
No Rights history available